Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected male or female subjects \>= 18 years of age~* Screening plasma HIV-1 RNA \>=1000 c/mL~* CD4+ cell count \>=200 cells/millimeter (mm)\^3~* ART-naive defined as having =\<10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection~* Female subjects of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy during the study~Exclusion Criteria:~* Any evidence at screening of an active Centers for Disease and Prevention Control (CDC) Category C disease~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening~* History of ongoing or clinically relevant hepatitis within the previous 6 months, and subjects with moderate to severe hepatic impairment will be excluded~* Women who are breastfeeding~* Subject, who in the investigator's judgment, poses a significant suicide risk~* Any clinically significant finding on screening or baseline electrocardiograph (ECG)~* The presence of any specific laboratory abnormalities at Screening~* History of cardiac disease~* Clinically relevant pancreatitis~* Subjects who are unlikely to complete the dosing schedule due to a pre-existing physical or mental condition~* Any condition which impairs the absorption, distribution, metabolism or excretion of the investigational product~* Any evidence of primary resistance based upon the presence of a major resistance associated mutation in the Screening HIV genotype, or any historical genotype~* Treatment with any protocol-specified excluded medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 GSK1265744 10 mg (Type: EXPERIMENTAL): In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
- Arm 2 GSK1265744 30 mg (Type: EXPERIMENTAL): In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
- Arm 3 GSK1265744 60 mg (Type: EXPERIMENTAL): In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
- Arm 4 Efavirenz 600 mg (Type: ACTIVE_COMPARATOR): In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).

Based on this trial design, predict the completion outcome and termination type (if applicable).